Blog

  • Lessons Learned: What Works (and Doesn’t) In Rare Disease Investing

    The rare disease space has long been a key investing focus for NEA’s healthcare practice, given several ideal characteristics for biopharma innovation capital: high unmet need; rapidly advancing science; and favorable clinical development paths. Rare genetic diseases often have severe or even fatal manifestations, with few treatments available, while emerging genetic data and new treatment modalities such as gene therapy are rendering monogenic diseases more tractable. Regulatory…

    • August 19, 2019

    Capsule Pharmacy 'Dear Doctor' Interview Series: Sara Nayeem

    *Interview of Sara Nayeem by Maya De La Rosa-Cohen; originally published as part of the Capsule 'Dear Doctor' Series, which highlights women physicians working throughout the field of healthcare. Dr. Sara Nayeem was selected three times as one of GrowthCap’s Top 40 Under 40 Growth Investors. Having earned her MD and MBA simultaneously from Yale University and worked within Merrill Lynch’s Global Healthcare Group, today she uses her knowledge and experience in both medicine and business…

  • Collective Health: Transforming an Industry by Focusing on Individuals

    When we first met Collective Health, it was 2014—American satisfaction with the health insurance industry had dipped to a 10-year low [1], the proliferation of mobile devices and cloud technology had already impacted major industries from IT to finance to real estate, and a new crop of startups were applying SaaS technology solutions across healthcare verticals—a trend that was increasing rapidly, and one which we followed closely. We focus on identifying companies that are addressing real…

  • How I Survived Insane Hypergrowth at Airbnb

    As I reflect on my time as Director of Product at Airbnb, I already feel a sense of nostalgia. I get another emotion, though, when I remember the harder times. Helping the business scale like crazy was a roller coaster, and there were many moments when I was ready to throw my hands up and jump on a plane to somewhere across the world (to quietly relax in an Airbnb, of course). Building a startup that is in hypergrowth is like few other professional experiences. The work environment is…

  • The Investor’s Dilemma: What Matters Most?

    People often ask VCs: What is the most important thing to look for in new investments? It’s a simple enough question, but the answer is actually pretty complicated. We look for disruption, and we look for impact. We look for teams and companies that are solving problems and challenging the status quo. More than anything, we look for the right people—for entrepreneurs who have a certain spark about them. Very rarely, the stars align so that all of those factors—the team, technology, and market…